Therapeutic effects of docosahexaenoic acid ethyl ester in patients with generalized peroxisomal disorders

103Citations
Citations of this article
43Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Generalized peroxisomal disorders are severe congenital diseases that involve the central nervous system, leading to severe psychomotor retardation, retinopathy, liver disease, and early death. In these disorders, peroxisomes are not normally formed and their enzymes are deficient. Characteristically, plasmalogen synthesis and β-oxidation of very-long-chain fatty acids (VLCFAs) are affected. We found that patients with generalized peroxisomal disorders have a profound brain deficiency of docosahexaenoic acid (DHA; 22:6n-3) and low DHA concentrations in all tissues and the blood. Given the fundamental role of DHA in neuronal and retinal membranes, a DHA deficiency of this magnitude might be pathogenic. Thus, we studied the possible therapeutic effect of normalizing DHA concentrations in patients with peroxisomal disorders. We chose the DHA ethyl ester (DHA-EE) because of its high degree of purity at daily oral doses of 100-500 mg. This article summarizes the results of treatment of 13 patients with DHA-EE, with some follow-up evidence of clinical improvement. Supplementation with DHA-EE normalized blood DHA values within a few weeks. Plasmalogen concentrations increased in erythrocytes in most patients and after DHA concentrations were normalized, amounts of VLCFAs decreased in plasma. Liver enzymes returned almost to normal in most cases. From a clinical viewpoint, most patients showed improvement in vision, liver function, muscle tone, and social contact. In 3 patients, normalization of brain myelin was detected by magnetic resonance imaging. In 3 others, myelination improved. In a seventh patient, myelination is progressing at a normal rate. These results suggest a fundamental role of DHA in the pathogenesis of Zellweger syndrome. DHA therapy is thus strongly recommended, not only to alleviate symptoms in patients with life-threatening diseases, but also to clarify remaining questions regarding the role of DHA in health and disease.

References Powered by Scopus

Peroxisomes (microbodies and related particles).

1189Citations
N/AReaders
Get full text

Peroxieomal and mitochondrial defects in the cerebro-hepato-renal syndrome

648Citations
N/AReaders
Get full text

Lignoceric acid is oxidized in the peroxisome: Implications for the Zellweger cerebro-hepato-renal syndrome and adrenoleukodystrophy

342Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Docosahexaenoic acid: Membrane properties of a unique fatty acid

704Citations
N/AReaders
Get full text

The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina

703Citations
N/AReaders
Get full text

Docosahexaenoic acid: A positive modulator of Akt signaling in neuronal survival

391Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Martínez, M., Vázquez, E., García-Silva, M. T., Manzanares, J., Bertran, J. M., Castelló, F., & Mougan, I. (2000). Therapeutic effects of docosahexaenoic acid ethyl ester in patients with generalized peroxisomal disorders. In American Journal of Clinical Nutrition (Vol. 71). American Society for Nutrition. https://doi.org/10.1093/ajcn/71.1.376s

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 11

41%

Researcher 7

26%

Lecturer / Post doc 5

19%

Professor / Associate Prof. 4

15%

Readers' Discipline

Tooltip

Medicine and Dentistry 13

45%

Agricultural and Biological Sciences 9

31%

Neuroscience 4

14%

Biochemistry, Genetics and Molecular Bi... 3

10%

Save time finding and organizing research with Mendeley

Sign up for free